Abstract A126: Change in status promoter of 5 panel gene during progression of atypical hyperplasia to breast cancer

• Published in: Molecular cancer therapeutics 2013-11, Vol.12 (11_Supplement), p.A126-A126
• Main Authors: Joaquina, Martínez-Galán, Delgado, Juan Ramon, Torres-Torres, Blanca, Del Moral, Rosario, Ríos, Sandra, Núñez, M. Isabel
• Format: Article
• Language: English
• ISSN: 1535-7163; 1538-8514
• DOI: 10.1158/1535-7163.TARG-13-A126

Background: DNA methylation is the main epigenetic modification in cancer. The pathological features of breast cancer follow a sequential progression from transition of a normal cell to benign proliferative hyperplasia, hyperplasia with atypia, in situ carcinoma and, eventually, to invasive and metastatic disease. Purpose: This study was designed to evaluate the changes in promoter CpG islands hypermethylation during breast cancer progression from pre-invasive lesions to invasive ductal carcinoma and different methylation patron with benign breast disease. Material and Methods: We performed analysis for the methylation status of 5 promoter CpG island (ESR1, E-Cad, APC, RARB, and 14-3-3-; promoters) in a group with women with normal breast tissue n=74; other group with epithelial atypia/ atypical ductal hyperplasia (n=20), ductal carcinoma in situ (DCIS, n=14) and invasive ductal carcinoma (IDC, n=107). Results: Relative serum levels of methylated gene promoters ESR1 and 14-3-3-; showed significant differences between IDC y normal breast tissue (were significantly higher in IDC than normal breast tissue) and between normal breast tissue and epithelial atypia/ atypical ductal hyperplasia/ ductal carcinoma in situ. There are no differences between IDC and epithelial atypia/ atypical ductal hyperplasia/ ductal carcinoma in situ when 14-3-3-; and ESR1 mean values are compared. In fact, the present findings showed a frequent presence of methylated 14-3-3-; in sera from women with breast benign disease, which could be considered the result of a proliferative alteration of epithelial and stromal components of the breast. Which may indicate presence of occult benign breast disease, although other possible sources of this DNA include normal tissues, which show higher methylation values with increasing age; which might undergo lysis during tumor growth; or premalignant lesion during tumor growth; or premalignant lesion. Conclusions: These findings showed that promoter CpG island methylation changed significantly in pre-invasive lesions, and breast cancer, suggesting that CpG island methylation of tumor-related genes is an early event in breast cancer progression. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A126. Citation Format: Martínez-Galán Joaquina, Juan Ramon Delgado, Blanca Torres-Torres, Rosario Del Moral, Sandra Ríos, M. Isabel Núñez. Change in status promoter of 5 panel gene during progression of atypical hyperplasia to breast cancer. [abstract].